PDGF-B conjugating mesoporous IO/GdO nanocomposites for accurate diagnosis of orthotopic prostatic cancer through T1-T2 dual-modal MRI contrast enhancement
Source abstract
Abstract
The development of highly efficient magnetic resonance imaging (MRI) contrast agent contributes to the early and accurate diagnosis of cancer. Herein, we developed a novel iron oxide and gadolinium oxide (IO/GdO) nanocomposite as T1-T2 dual modal MRI contrast agent through hydrothermal synthesis method. Subsequently, tumor-targeting ligand (PDGFB-PEG) was further conjugated to the surface of IO/GdO nanocomposite (PDGFB-pIO/GdO) to fabricate tumor-targeting MRI probe for accurate diagnosis of orthotopic prostatic cancer. IO/GdO nanocomposite exhibited obvious mesoporous structure, which would promote the contact between water molecules and Gd or Fe centers and enhance the T1 relaxation rate (r1) and T2 relaxation rate (r2) of IO/GdO composite. In addition, the r1 and r2 values of IO/GdO composite were up to be 11.6 mM−1s−1 and 102.7 mM−1s−1, respectively, and the r2/r1 ratio of IO/GdO nanocomposite was calculated to be 8.85, demonstrating a great potential as dual-mode MRI contrast agent. Further study indicated that PDGFB-pIO/GdO exhibited an excellent biocompatibility. Besides, PDGFB-pIO/GdO presented a higher accumulation in tumor than untargeted pIO/GdO, confirming its excellent in vivo tumor-targeting ability. Lastly, in orthotopic prostatic cancer model, the systemic delivery of PDGFB-pIO/GdO significantly enhanced T1- and T2-weighted signal of orthotopic prostatic cancer, achieving high quality of MR images and realizing accurate diagnosis of orthotopic prostatic cancer. Collectively, we proposed a rational designed nanoplatform, PDGF-B conjugating mesoporous IO/GdO nanocomposites, suggesting potential for diagnostic identification of prostate cancer via T1-T2 dual-modal MRI contrast enhancement.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Lanthanide and Transition Metal Complexes · Luminescence Properties of Advanced Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Engineering of inorganic nanoparticles as magnetic resonance imaging contrast agents10.1039/C7CS00316A ↗
2. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging10.1021/ja0422155 ↗
3. Oxygen-enriched Fe3O4/Gd2O3 nanopeanuts for tumor-targeting MRI and ROS-triggered dual-modal cancer therapy through platinum (IV) prodrugs delivery10.1016/j.cej.2020.124269 ↗
4. Contrast agents: magnetic resonance10.1007/978-3-540-72718-7_7 ↗
5. Target-switchable Gd(III)-DOTA/protein cage nanoparticle conjugates with multiple targeting affibody molecules as target selective T1 contrast agents for high-field MRI10.1016/j.jconrel.2021.05.029 ↗
6. Stimulus-responsive nanoparticle magnetic resonance imaging contrast agents: design considerations and applications10.1002/adhm.202001091 ↗
7. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T10.1097/RLI.0000000000000132 ↗
8. Synthesis of water-dispersible Gd2O3/GO nanocomposites with enhanced MRI T1 relaxivity10.1021/acs.jpcc.5b06037 ↗
9. An MRI-sensitive, non-photobleachable porphysome photothermal agent10.1002/anie.201400133 ↗
10. Localized nanotheranostics: recent developments in cancer nanomedicine, Mater
11. Dual-mode avocado-like all-iron nanoplatform for enhanced T1/T2 MRI-guided cancer theranostic therapy10.1021/acs.nanolett.0c00817 ↗
12. Oxygen vacancy defect-induced activity enhancement of Gd doping magnetic nanocluster for oxygen supplying cancer theranostics10.1021/acsami.0c09952 ↗
13. Functional magnetic porous silica for T1-T2 dual-modal magnetic resonance imaging and pH-responsive drug delivery of basic Drugs10.1088/0957-4484/27/48/485702 ↗
14. Magnetic nanoparticle-based solid phase peptide synthesis and the synchronous detection of their biological activity
15. Gadolinium(III)-based blood-poolcontrast agents for magneticresonance imaging: status and clinical potential10.1517/17425247.4.2.149 ↗
16. Quantitative proteomics of TRAMP mice combined with bioinformatics analysis reveals that PDGF-B regulatory network plays a key role in prostate cancer progression10.1021/acs.jproteome.8b00158 ↗
17. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma10.1093/brain/awaa382 ↗
18. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier10.1016/j.jconrel.2010.03.018 ↗
19. Characterization of Fe3O4/SiO2/Gd2O(CO3)2 core/shell/shell nanoparticles as T1 and T2 dual mode MRI contrast agent10.1016/j.talanta.2014.08.042 ↗
20. Magnetic relaxation switch detecting boric acid or borate ester through one-pot synthesized poly(vinyl alcohol) functionalized nanomagnetic iron oxide10.1021/acsami.5b04863 ↗
21. Albumin-mediated synthesis of fluoroperovskite KMnF3 nanocrystals for T1-T2 dual-modal magnetic resonance imaging of brain gliomas with improved sensitivity10.1016/j.cej.2020.125066 ↗
22. T1 and T2 dual-mode MRI contrast agent for enhancing accuracy by engineered nanomaterials10.1021/nn405977t ↗
23. Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents10.1038/s41598-018-22511-6 ↗
24. Tunable T1 and T2 contrast abilities of manganese engineered iron oxide nanoparticles through size control10.1039/C4NR02680B ↗
25. Interplay between longitudinal and transverse contrasts in Fe3O4 nanoplates with (111) exposed surfaces10.1021/nn5038652 ↗
26. Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging10.1021/nn305991e ↗
27. Water-dispersible ferrimagnetic iron oxide nanocubes with extremely high r2 relaxivity for highly sensitive in vivo MRI of tumors10.1021/nl3010308 ↗
28. Influence of morphology and surface exchange reaction on magnetic properties of monodisperse magnetite nanoparticles10.1016/j.colsurfa.2012.05.039 ↗
29. Octapod iron oxide nanoparticles as high performance T2 contrast agents for magnetic resonance imaging10.1038/ncomms3266 ↗
30. A synergistically enhanced T1-T2 dual-modal contrast agent10.1002/adma.201203169 ↗
31. Gadolinium-doped iron oxide nanoprobe as multifunctional bioimaging agent and drug delivery system10.1002/adfm.201502868 ↗
32. Gadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agent10.1021/nn302393e ↗
33. Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T1- and T2-weighted magnetic resonance imaging10.1021/bc900424u ↗
34. Core/shell Fe3O4/Gd2O3 nanocubes as T1-T2 dual modal MRI contrast agents10.1039/C6NR02620F ↗
35. S-Gal, A novel 1H MRI reporter for beta-galactosidase10.1002/mrm.22400 ↗
36. Human cardiac 31P magnetic resonance spectroscopy at 7 Tesla10.1002/mrm.24922 ↗
37. Paramagnetic and superparamagnetic inorganic nanoparticles for T1-weighted magnetic resonance imaging
38. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles10.1016/j.biomaterials.2011.03.018 ↗